On Tuesday, Shares of Century link Inc (NYSE:CTL), lost -0.76% to $28.59.
CenturyLink, declared that its Board of Directors voted to declare a regular quarterly cash dividend of $0.54 per share on December 8, 2015, to shareholders of record on November 24, 2015.
CenturyLink, Inc. provides various communications services to residential, business, governmental, and wholesale customers in the United States. It operates through two segments, Business and Consumer.
Shares of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), inclined 2.15% to $64.12, during its last trading session.
Isis Pharmaceuticals, stated merged financial results for the third quarter of 2015 and highlighted recent progress in advancing its pipeline.
“Our drugs in development have the potential to make fundamental changes in the way diseases are treated. Our pipeline is large, with numerous late-stage programs that represent potential near term commercial opportunities. We are conducting four Phase 3 studies which should complete enrollment in the next several months. And, we believe these programs have each been substantially de-risked by positive data from Phase 2 studies. Just last week, we stated encouraging data from two Phase 2 studies of ISIS-TTRRx, which support the potential benefit of ISIS-TTRRx for patients with familial amyloid polyneuropathy, FAP, and TTR amyloid cardiomyopathy. Together with our partner, GSK, we are conducting a broad Phase 3 program evaluating ISIS-TTRRx in all forms of TTR amyloidosis. As part of this program, GSK plans to initiate a Phase 3 study of ISIS-TTRRx in patients with TTR amyloid cardiomyopathy, both familial and wild type, early next year. Further, we expect to complete enrollment in our Phase 3 study of ISIS-TTRRx in patients with FAP by year end,” said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals. “Our other Phase 3 programs are also progressing well. We expect to complete enrollment in both of our Phase 3 studies of nusinersen, the generic name for ISIS-SMNRx, in infants and in children with spinal muscular atrophy by early next year. In addition, we and Akcea plan to complete enrollment in the Phase 3 study of volanesorsen in patients with familial chylomicronemia syndrome this year. We also plan to start dosing patients in our Phase 3 study of volanesorsen in patients with familial partial lipodystrophy by the end of the year. As enrollment nears completion for the ongoing Phase 3 studies for ISIS-TTRRx, nusinersen and volanesorsen, we and our partners are working closely together to prepare for regulatory filings and to prepare the drugs for the market.”
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
Finally, Shares of Penn West Petroleum Ltd (USA) (NYSE:PWE), ended its last trade with 0.75% gain, and closed at $1.34.
Penn West Petroleum Ltd, declare that it has closed the sale of its non-operated 9.5% working interest in the Weyburn Unit in Southeast Saskatchewan for cash consideration of about $205 million.
Additionally, as declared in our third quarter results, we closed the sale of our properties in the Greater Mitsue area of Central Alberta on October 30, 2015, for total proceeds of $193 million, subject to closing adjustments. We intend to use the proceeds from both dispositions to reduce our senior debt.
With about $810 million in divestitures declared this year, we have surpassed our $650 million non-core asset disposition target, despite a challenging commodity price environment. These transactions continue to demonstrate our ability to complete non-core asset dispositions at attractive deal metrics. We will continue our divestiture process on additional non-core assets.
Penn West Petroleum Ltd. explores for, develops, and produces oil and natural gas properties in western Canada. The company’s properties are located in Alberta, British Columbia, Saskatchewan, Manitoba, and the Northwest Territories, Canada; and Wyoming, the United States.